JavaScript is currently not supported/disabled by this browser. Please enable JavaScript for full functionality.

Call Us 1 - 866 - 986 - 9598
[email protected]

Sign Up

Login
- My Order
- Return Requests
- Track my Order

Home / Cells / Cell Lines

Anti-BCMA CAR-T Cells

SKU : BHC18200281

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Request More Infos

BPS Bioscience

view supplier details

Order Now

Credit card payments now incur a 3% fee.

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Ask Merchant

Request More Infos

Sample Request

Mfr.No.	78660-1
Description	The anti-BCMA CAR-T cells are produced by high-titer lentiviral transduction of human primary CD4+CD8+ T cells using the anti-BCMA CAR Lentivirus (Biohippo #78655). These ready-to-use CAR-T cells express an anti-BCMA CAR consisting of the ScFv of BCMA (clone C11D5.3) linked to a 2^nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3zeta signaling domains (Figure 1). These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays. Mycoplasma testing: The cells have been screened to confirm the absence of Mycoplasma species. Host Species: human Supplied as Each vial contains 2 x 10⁶ cells in 1 ml of CryoStor CS10
Background	B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in nonmalignant tissue but almost universal expression on MM cells. So far FDA has approved two BCMA CAR-T therapies for the treatment of multiple myeloma.
Application	Positive control for anti-BCMA CAR-T cellsScreen inhibitors or activators of anti-BCMA CAR-T cytotoxicityDesign and optimize co-culture cytotoxicity assay
Shipping Temperature	-80°C (dry ice)
Note	Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate biological safety level 2 precautions should be used.Biosafety: The anti-BCMA CAR-T cells are produced with the third generation SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle.Troubleshooting Guide For all further questions, please email [email protected]. Waing: Avoid freeze/thaw cycles. Donors have been screened and determined negative for:Hepatitis B (anti-HBc EIA, HBsAg EIA)Hepatitis C (anti-HCV EIA)Human Immunodeficiency Virus (HIV-1/HIV-2 plus O)Human T-Lymphotropic Virus (HTLV-I/II)HIV-1/HCV/HBVWest Nile VirusTrypanasoma cruzi

Storage Stability	Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.

Product Manual	Datasheet

Have you used this product?

Rate it now..!!

Login to Review

SKU	Supplier No.	Size	Your price	Quantity
BHC18200281	78660-1	1 vial	$1754.50		Add to Cart

ebiohippo.com provides biomedical researchers with a one-stop informatic shopping experience by transforming biotechnology products’ data into a ready-to-analyze state. We collect and unify suppliers’ data on a single platform to reduce the time of searching, uncertainty, and cost of scientific experiments.

© 2024 Biohippo. All rights reserved.